Pharmacogenetics

Pharmacogenetics is the study of how your genetic makeup influences the way your body metabolizes medications. Every person carries a unique set of enzyme variants — particularly in the cytochrome P450 family — that can make a drug work perfectly, cause dangerous side effects, or render it completely ineffective. Understanding these variants is no longer a luxury reserved for research labs; it is becoming a cornerstone of modern personalized medicine.

At the center of pharmacogenetic testing are genes like CYP2D6 and CYP2C19, which together metabolize roughly 40% of all commonly prescribed drugs, including antidepressants, beta-blockers, opioids, and proton-pump inhibitors. A single nucleotide change in CYP2D6 can turn a patient into a "poor metabolizer," meaning standard doses accumulate to toxic levels, or an "ultra-rapid metabolizer," where the drug is cleared so fast it never reaches therapeutic concentration. Clinical studies have shown that CYP2D6 testing before prescribing codeine can prevent life-threatening respiratory depression, especially in children.

Beyond the CYP family, genes such as DPYD (critical for fluorouracil chemotherapy safety), TPMT (essential for thiopurine dosing in autoimmune diseases and leukemia), and SLCO1B1 (linked to statin-induced muscle damage) play pivotal roles in drug safety. The FDA now includes pharmacogenetic information on the labels of over 300 medications, and leading health systems worldwide are integrating preemptive genetic testing into routine care.

For consumers who have already taken a direct-to-consumer DNA test through services like 23andMe or AncestryDNA, the raw data file contains many of these pharmacogenetic variants. By uploading your genome to Ask My DNA, you can explore your CYP2D6, CYP2C19, DPYD, and VKORC1 status and have an informed conversation with your healthcare provider about whether your current medications are optimally dosed for your unique genetic profile.